Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EVT planning to restart EndoVascular Grafting System trials by year-end.

This article was originally published in The Gray Sheet

Executive Summary

ENDOVASCULAR TECHNOLOGIES ENDOVASCULAR GRAFTING SYSTEM CLINICALS are expected to recommence before the end of 1995, company President and CEO Jim Fitzsimmons said at a May 16 session of the Alex. Brown & Sons Health Care Seminar in Baltimore. Earlier this year, the privately held company voluntarily suspended two trials following discovery of breaks in the attachment component of the grafting system ("The Gray Sheet" Feb. 27, p. 13). The suspended studies -- a Phase II trial of the EndoGraft tube vascular graft implant and a Phase I study of the bifurcated EndoGraft -- were evaluating the systems in the treatment of abdominal aortic aneurysms.

You may also be interested in...

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.


ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Start-Up Snapshot: Nanomedic’s Electro-Spinning, Portable Wound Care Device

At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts